logo
Why TMC The Metals Company Stock Sank 10% Last Month and Has Kept Falling in August

Why TMC The Metals Company Stock Sank 10% Last Month and Has Kept Falling in August

Yahooa day ago
Key Points
TMC stock lost ground in July as the U.S. made some significant concessions in order to advance trade negotiations with China.
Striking a deal for access to Chinese rare earth minerals is at the heart of the U.S.'s aims in trade negotiations, and this raises questions for TMC.
A trade deal between the U.S. and China could soften TMC's growth trajectory, but the company still has big opportunities in domestic mineral sourcing.
10 stocks we like better than TMC The Metals Company ›
TMC The Metals Company (NASDAQ: TMC) stock got hit with a significant pullback in July's trading. The company's share price slumped 10% in a month of trading that saw the S&P 500 index rise 2.2% and the Nasdaq Composite index jump 3.7%.
While the broader market rose in relation to developments that suggested that the U.S. and China could be moving closer to a trade deal that would lower tariffs and resolve other key issues, TMC stock saw a pullback as a result of the news. On the other hand, recent pullbacks for its share price come on the heels of a massive valuation run-up for the company this year.
TMC stock lost ground amid U.S.-China trade developments
Last month, the Trump administration announced that it was lifting licensing requirements and export restrictions that effectively prohibited high-end artificial intelligence (AI) chips from Nvidia and AMD from being sold to the Chinese market. Export restrictions and licensing requirements on semiconductor manufacturing equipment are also being lifted. The big shift on key tech exports to China represented a concession from President Donald Trump in order to increase the likelihood of getting serious negotiations for a trade deal initiated in the not-too-distant future.
While the Trump administration has seemingly been willing to cede some key ground when it comes to some of the U.S.'s competitive advantages in AI, it's hoping that the move will help secure longer-term access to China's rare earth mineral supply. Adversarial relations between the U.S. and China have increased the strategic importance of domestic mineral sourcing operations and paved the way for TMC stock to see huge gains this year. With some recent steps toward trade negotiations between the U.S. and China, TMC's big rally has taken a bit of a breather.
TMC's share price has continued to slide in August
As of this writing, TMC stock is down roughly 10% in August's trading. While there haven't been any major, negative business-specific catalysts for the company, investors have continued to take profits and reduce exposure to the stock in light of uncertain trade dynamics. Despite some recent sell-offs, the company's share price is still up roughly 378% year to date as of this writing.
TMC now has a market capitalization of roughly $1.9 billion and is still in a pre-revenue state. While the company will still need to secure key permitting and other regulatory approvals in order to kick off its commercial seabed mining operations, there seems to be a good chance that increased government support for domestic rare earth mining projects will help facilitate TMC's operational launch and scaling.
Betting on that outcome is still a risky proposition, but an executive order signed by President Trump to expedite the review of permitting applications for seabed-mining bodes well for the company. While a trade deal with China could help alleviate near-term concerns about rare earth mineral sourcing, increasing domestic production capabilities will likely continue to be a priority along economic and national security lines.
Should you buy stock in TMC The Metals Company right now?
Before you buy stock in TMC The Metals Company, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TMC The Metals Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!*
Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 11, 2025
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why TMC The Metals Company Stock Sank 10% Last Month and Has Kept Falling in August was originally published by The Motley Fool
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Yahoo

time23 minutes ago

  • Yahoo

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio

Why SoundHound AI's (SOUN) Amelia Acquisition Could Pay Off in the Long Run
Why SoundHound AI's (SOUN) Amelia Acquisition Could Pay Off in the Long Run

Yahoo

timean hour ago

  • Yahoo

Why SoundHound AI's (SOUN) Amelia Acquisition Could Pay Off in the Long Run

SoundHound AI, Inc. (NASDAQ:SOUN) is one of the AI Stocks Analysts Are Watching Closely. On August 11, Ladenburg Thalmann analyst Glenn Mattson upgraded the stock from Neutral to Buy with a price target of $16.00 (from $9.00). The rating upgrade comes after Soundhound posted second-quarter revenue well above expectations driven by its large contract wins. According to the firm, momentum in core verticals is helping offset previous concerns about low-margin contracts from the Amelia acquisition. These are anticipated to be phased out over the next 18 months. The firm also believes that SoundHound is building a broader platform that may link automotive, restaurant and enterprise customers into a voice-enabled ecosystem. This will in turn create lead-generation revenue streams. A Wall Street analyst reviewing stock information on a computer, examining data points for a new investment opportunity. 'We upgrade shares to Buy and raise our PT to $16 (from $9). We continue to view Voice as one of the key early applications for AI systems. The company is a leader in this space and is adding significant utility for enterprises looking to adopt AI functionality. The Amelia acquisition still needs further integration but is providing solid benefits in terms of scale, new lead generation, and an entry into the enterprise. While valuation remains elevated, the growth and scale justify that premium, in our view. We now use a 22x multiple on our new 2027 estimate to achieve our $16 PT. This is justified by the rule of 40 peer set found in the body of the report.' SoundHound AI, Inc. (NASDAQ:SOUN) is a voice artificial intelligence company offering voice AI solutions to businesses. While we acknowledge the potential of SOUN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store